Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis

European Journal of Dermatology

Volumn 17, Issue 5, 2007, Pages 381-386

  Reich, Kristian ^a   Nestle, Frank O ^b   Wu, Ying ^c   Bala, Mohan ^c   Eisenberg, Debra ^c   Guzzo, Cynthia ^c   Li, Shu ^c   Dooley, Lisa T ^c   Griffiths, Christopher E M ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CENTOCOR INC   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Infliximab; Productivity; Psoriasis; Quality of life

Indexed keywords

INFLIXIMAB; PLACEBO;

ADULT; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRODUCTIVITY; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EFFICIENCY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548711281     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2007.0234     Document Type: Article

References (31)

1. Finlay AY, Kelly SE. Psoriasis - an index of disability. Clin Exp Dermatol 1987; 12: 8-11.
2. Richards HL, Fortune DG, Griffiths CEM, Main CJ. The contribution of perceptions of stigmatization to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-5.
3. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-92.
4. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol 1993; 32: 188-90.
5. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-8.
6. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Arch Dermatol 2001; 137: 280-4.
7. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44.
8. Wu Y, Mills D, Bala M. Psoriasis has a significant negative impact on patients' work and productivity. J Invest Dermatol 2005; 125: A77; (abstract).
9. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006; 17: 24-8.
10. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
12. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
13. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind, placebo-controlled trial. Br J Dermatol 2005; 152: 954-60.
14. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
15. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 10.1016/j.jaad.2006.07.017.
16. Reich K, Nestle F, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis. Br J Dermatol 2006; 154: 1161-8.
17. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6.
18. Ware JE, Kosinski M, Keller SD. Interpretation: Norm Based. In: SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston MA: The Health Institute, 1994: 1-42.
19. Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: A multicenter cost-of-illness study. Dermatology 2006; 212: 137-44.
20. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
21. van der Heijde D, Han C, DeVlam K, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Rheum 2006; 55: 569-74.
22. Kavanaugh A, Antoni C, Mease P, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheum 2006; 33: 2254-9.
23. Ware JE, Gandek B, Ksoinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA project. J Clin Epidemiol 1998; 51: 1167-70.
24. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-64.
25. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003; 41: 582-92.
26. Ware JE, Kosinski M, Gandek B. In: Applications for the SF-36™. SF-36 Health Survey Manual and Interpretation Guide. Lincoln. RI: Quality Metric Inc 2004; 10: 14.
27. Krueger GG, Bergstresser PR, Lowe NJ, Voorhees JJ, Weinstein GD. Psoriasis. J Am Acad Dermatol 1984; 11: 937-47.
28. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46: 850-60.
29. Wahlqvist P, Carlsson J, Stalhammar N-O, et al. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastroesophageal reflux disease (WPAI-GERD)-Results from a cross-sectional study. Value Health 2002; 5: 106-13.
30. Shikiar R, Halpern MT, Rentz AM, Khan ZM. Development of the Health and Work Questionnaire (HWQ): an instrument for assessing workplace productivity in relation to worker health. Work 2004; 22: 219-29.
31. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.